Research Library › Peptide Fragments
ARA-290, now known by the nonproprietary name cibinetide, is a synthetic 11-amino-acid peptide (pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser). It is modeled on the aqueous face of helix B of the hormone erythropoietin (EPO). Michael Brines, Anthony Cerami and colleagues described it in 2008, and Araim Pharmaceuticals developed it. As of 23 Oct 2026 it holds U.S. and EU orphan designations but is not approved by the FDA or any other regulator.
Key facts
| Type | Synthetic linear peptide, 11 amino acids |
|---|---|
| Sequence | pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser |
| Derived from | Aqueous face of helix B (residues 58-82) of erythropoietin |
| First described | 2008, Proceedings of the National Academy of Sciences (Brines, Cerami et al.) |
| Developed by | Michael Brines and Anthony Cerami; sponsor Araim Pharmaceuticals, Inc. (New York) |
| Designed target | Proposed tissue-protective receptor: EPO receptor/CD131 (beta common receptor) heterocomplex |
| Regulatory status (Oct 2026) | Not FDA-approved; FDA orphan designations 2011 and 2016; EU orphan designation 2013; FDA 503A Category 3 |
Who developed it
ARA-290 was described in 2008 in the Proceedings of the National Academy of Sciences by a 16-author team led by Michael Brines and Anthony Cerami, with collaborators in Italy, Turkey, Portugal and the United Kingdom [1]. Cerami, a biochemist, and Brines had spent years studying non-blood-forming roles of erythropoietin.
Clinical development was taken up by Araim Pharmaceuticals, Inc., which FDA records list at addresses in Ossining and later Tarrytown, New York [2, 3]. A European affiliate, Araim Pharmaceuticals Europe Limited (Ireland), took over the EU orphan sponsorship in April 2019 [4]. The compound later received the nonproprietary name cibinetide [4].
What it was designed to target
Erythropoietin binds a pair of identical EPO receptors (a homodimer) to drive red blood cell production. Brines and Cerami proposed that a separate receptor, made of one EPO receptor paired with CD131 (the beta common receptor), mediates EPO’s tissue-protective signaling [1].
The 2008 team mapped this activity to helix B of EPO (residues 58 to 82), the face that points into the surrounding fluid when EPO is bound to its classic receptor. They then designed an 11-amino-acid peptide from that surface, which became ARA-290 [1]. The design aim was to separate the proposed tissue-protective signaling from red cell production. In their preclinical studies, neither helix B peptide stimulated erythropoiesis [1]. The peptide begins with pyroglutamate, a cyclized form of glutamine, as reflected in FDA’s orphan listing [2].
Why it was created
Recombinant EPO was already an approved drug for anemia. Its blood-thickening activity, however, limited its study for other purposes. ARA-290 was created to study EPO-like tissue-protective signaling without that erythropoietic activity [1].
Araim’s clinical program was originally investigated in sarcoidosis, focusing on small fiber neuropathy associated with that disease, through Phase II studies [5]. This work led to orphan designations: in the U.S. for neuropathic pain in sarcoidosis (2011) and for sarcoidosis (2016), and in the EU for sarcoidosis (2013) [2, 3, 4].
Research timeline
- 2008: Brines, Cerami and colleagues describe tissue-protective peptides derived from EPO helix B in PNAS [1].
- 13 Sep 2011: FDA orphan designation for neuropathic pain in patients with sarcoidosis, sponsor Araim Pharmaceuticals [2].
- 7 Oct 2013: European Commission orphan designation EU/3/13/1191 for sarcoidosis [4].
- 2014: Review of two Phase II trials in sarcoidosis-associated small fiber neuropathy published [5].
- 13 Jun 2016: Second FDA orphan designation, for sarcoidosis [3].
- Apr 2019: EU orphan sponsorship transferred to Araim Pharmaceuticals Europe Limited, Ireland [4].
Regulatory status as of October 2026
As of 23 Oct 2026, cibinetide is not approved by the FDA, the European Medicines Agency or any other major regulator. FDA’s orphan database lists both U.S. designations as “Designated” and “Not FDA Approved for Orphan Indication” [2, 3]. An orphan designation is not a marketing authorization [4].
On FDA’s list of bulk drug substances nominated for 503A compounding (updated 14 May 2026), “Cibinetide (ARA-290)” appears in Category 3, bulk drug substances nominated without adequate support [6]. It is not on the Category 2 safety-risk list [7], and it was not on the 2026 agendas of FDA’s Pharmacy Compounding Advisory Committee [8].
Available from Kalibra Labs
Supplied as a lyophilized research material with a Certificate of Analysis matched to each lot number.
Frequently asked questions
What is ARA-290 derived from?
ARA-290 is an 11-amino-acid peptide modeled on the aqueous face of helix B of erythropoietin (EPO). It is designed to keep EPO’s proposed tissue-protective signaling but not its red blood cell activity.
Who developed ARA-290?
Michael Brines and Anthony Cerami described it with colleagues in 2008. Araim Pharmaceuticals, Inc. sponsored its clinical development.
What is cibinetide?
Cibinetide is the nonproprietary name given to ARA-290.
Is ARA-290 FDA approved?
No. As of 23 Oct 2026 it holds FDA orphan designations (2011 and 2016) but no approval. FDA’s 503A nomination list places it in Category 3.
Sources
- Brines M, Patel NSA, Villa P, Brines C, Mennini T, De Paola M, Erbayraktar Z, Erbayraktar S, Sepodes B, Thiemermann C, Ghezzi P, Yamin M, Hand CC, Xie QW, Coleman T, Cerami A. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci U S A. 2008;105(31):10925-10930. doi:10.1073/pnas.0805594105 Link
- U.S. FDA, Office of Orphan Products Development. Orphan designation: L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser, treatment of neuropathic pain in patients with sarcoidosis; designated 13 Sep 2011; sponsor Araim Pharmaceuticals, Inc. Link
- U.S. FDA, Office of Orphan Products Development. Orphan designation: L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser, treatment of sarcoidosis; designated 13 Jun 2016; sponsor Araim Pharmaceuticals, Inc. Link
- European Medicines Agency. EU/3/13/1191: Orphan designation for the treatment of sarcoidosis (cibinetide); designated 7 Oct 2013. Link
- van Velzen M, Heij L, Niesters M, Cerami A, Dunne A, Dahan A, Brines M. ARA 290 for treatment of small fiber neuropathy in sarcoidosis. Expert Opin Investig Drugs. 2014;23(4):541-550. doi:10.1517/13543784.2014.892072 Link
- U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (updated 14 May 2026). Link
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 22 Apr 2026). Link
- Latham & Watkins. FDA on Peptides: A New Landscape for Compounders (2026), summarizing 91 Fed. Reg. 20465 (16 Apr 2026) and the PCAC meeting agendas. Link
Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.
For Research Use Only. Kalibra Labs supplies this compound as a lyophilized research material for in-vitro laboratory use. It is not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page is a scientific and historical reference; it is not medical advice and makes no claim about use in people or animals.
